Vaccine Clinical Trials

6 recruiting

Vaccine Trials at a Glance

73 actively recruiting trials for vaccine are listed on ClinicalTrialsFinder across 6 cities in 30 countries. The largest study group is Not Applicable with 18 trials, with the heaviest enrollment activity in Taipei, Atlanta, and Chengdu. Lead sponsors running vaccine studies include Fondazione IRCCS Policlinico San Matteo di Pavia, National Taiwan University Hospital, and Canadian Immunization Research Network.

Treatments under study

About Vaccine Clinical Trials

Looking for clinical trials for Vaccine? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Vaccine trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Vaccine clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 73 trials

Recruiting
Phase 2

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer

Squamous Cell Carcinoma of the Head and NeckDrug TherapyOropharynx+2 more
National Cancer Institute (NCI)70 enrolled1 locationNCT06223568
Recruiting

Genomics and COVID-19 Vaccine Adverse Events

Vaccine Adverse Reaction
University of British Columbia6,325 enrolled1 locationNCT05212792
Recruiting

National, Non Interventional Study of Invasive Pneumococcal Disease in Children and Newborns

MortalityPneumococcal InfectionsPneumococcal Conjugate Vaccine+1 more
Association Clinique Thérapeutique Infantile du val de Marne2,500 enrolled1 locationNCT04664556
Recruiting

National Bacterial Meningitis Study in Children and Newborns

MeningitisChildren, OnlyNeonatal Infection+5 more
Association Clinique Thérapeutique Infantile du val de Marne10,000 enrolled1 locationNCT04664569
Recruiting
Phase 3

A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years

Varicella (Chickenpox)Chickenpox Vaccine
GC Biopharma Corp474 enrolled1 locationNCT07054099
Recruiting

Comprehensive Characterization of Immune Response Induced by Adjuvanted Glycoprotein E (gE)-Based Recombinant VAccine Zoster in Vulnerable Population Receiving ImmunOmodulaNt Therapies

RZV Vaccine (Shingrix ®)
Fondazione IRCCS Policlinico San Matteo di Pavia150 enrolled1 locationNCT07534007
Recruiting
Phase 1

Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.

Refractory Malignant Solid TumorsmRNA VaccineInterleukin
West China Hospital6 enrolled2 locationsNCT07040943
Recruiting
Not Applicable

Safety and Immunogenicity of Recombinant Zoster Vaccine for Transplant Recipients

ImmunosuppressionVaccine Response Impaired
Central Adelaide Local Health Network Incorporated160 enrolled1 locationNCT06262776
Recruiting
Phase 3

Shingrix in Renal Transplant Recipients

Kidney FailureKidney TransplantationKidney Failure, Chronic+2 more
University of Colorado, Denver132 enrolled4 locationsNCT04128189
Recruiting

Vaccine Confidence Study Among Historically Marginalized Racial and Ethnic Groups

Vaccine RefusalVaccine Hesitancy
Boston Medical Center80 enrolled1 locationNCT06639386
Recruiting
Not Applicable

A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor

TreatmentSolid Tumor CancerVaccine+1 more
Fudan University9 enrolled1 locationNCT06682117
Recruiting
Not Applicable

The Effect of a Transtheoretical Model-Based Educational Intervention on First-Year Nursing Students' HPV Knowledge, Health Beliefs, and Vaccination Behavior Intentions

Health Knowledge, Attitudes, PracticeHealth BehaviorHuman Papillomavirus (HPV)+2 more
Cukurova University88 enrolled2 locationsNCT07248904
Recruiting

Impact Of Kidney Failure On The Regulation Of Humoral Response To Vaccination

Chronic Kidney Disease Requiring Chronic DialysisVaccine Response
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico146 enrolled3 locationsNCT06635525
Recruiting
Not Applicable

Addressing Unfunded Vaccines Through a Co-payment Mechanism in Pharmacies

Preventable Disease, Vaccine
Canadian Immunization Research Network600 enrolled2 locationsNCT06489964
Recruiting

Understanding Immunity to the Flu Vaccine in COVID-19 Patients

ImmunityCorona Virus InfectionFlu Vaccine
Stanford University230 enrolled1 locationNCT04579588
Recruiting
Phase 3

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination

Pneumococcal Vaccines
Vaxcyte, Inc.720 enrolled30 locationsNCT07425392
Recruiting

Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?

Vaccination FailureVaccine Response Impaired
University of Alberta200 enrolled1 locationNCT05923970
Recruiting

Factors Affecting Vaccine Prophylaxis Efficacy in Bone Marrow and Solid Organ Transplant Recipients: Impact on Infection and Mortality Rates

Vaccine Prophylaxis
Fondazione IRCCS Policlinico San Matteo di Pavia200 enrolled1 locationNCT07473999
Recruiting
Not Applicable

The STOP-HPV Scale Up Study

Human Papilloma Virus Vaccine
University of California, Los Angeles100,000 enrolled1 locationNCT06831383
Recruiting
Not Applicable

Estimate the Safety and Effectiveness of Adjuvanted Influenza Vaccine Among Asian Elderly People When Compared to Non-adjuvanted Vaccines

ElderlyInfluenza Vaccines
National Taiwan University Hospital200 enrolled1 locationNCT06676644